| Not Yet Recruiting | XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation NCT05275374 | Xynomic Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Recruiting | Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2) NCT06813365 | Dizal Pharmaceuticals | Phase 1 |
| Recruiting | Patient-centered, Optimal Integration of Survivorship and Palliative Care NCT04900935 | Massachusetts General Hospital | N/A |
| Recruiting | A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer NCT06147570 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 2 |
| Completed | Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLC NCT05873439 | H. Lee Moffitt Cancer Center and Research Institute | EARLY_Phase 1 |
| Recruiting | Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tu NCT05283330 | Orano Med LLC | Phase 1 |
| Withdrawn | Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment NCT04625699 | Catherine Shu | Phase 2 |
| Active Not Recruiting | Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS NCT05688280 | Immunophotonics, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutati NCT05358249 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | A Study of [14C]GB491 in Male Healthy Subjects NCT05860582 | Genor Biopharma Co., Ltd. | Phase 1 |
| Completed | Role of Neutrophils and Electro-bioluminescence in the Rehabilitation NCT06209229 | MIPO Clinic | Phase 1 |
| Unknown | TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung C NCT05284994 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 / Phase 2 |
| Completed | A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in NCT05082610 | Hummingbird Bioscience | Phase 1 |
| Active Not Recruiting | Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population NCT05863052 | University of Oklahoma | — |
| Active Not Recruiting | NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastat NCT04984811 | NeoImmuneTech | Phase 2 |
| Recruiting | Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated Wit NCT04253964 | Wake Forest University Health Sciences | Phase 2 |
| Terminated | First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b NCT04396340 | Mersana Therapeutics | Phase 1 |
| Terminated | Metabolic and Microbial Profiling of Lung Cancer NCT03998189 | Wake Forest University Health Sciences | N/A |
| Unknown | Clinical Study of Anlotinib in Maintenance Treatment of Advanced NSCLC NCT03769805 | The First Affiliated Hospital with Nanjing Medical University | N/A |
| Unknown | Study of Lorlatinib in ROS1 Rearranged NSCLC NCT03612154 | National Cancer Center, Korea | Phase 2 |
| Active Not Recruiting | X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases NCT03753685 | Fudan University | Phase 2 |
| Unknown | CT-based Radiomic Signature Can Identify Adenocarcinoma Lung Tumor Histology NCT03940846 | Maastricht University | — |
| Recruiting | TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors NCT03778814 | Second Affiliated Hospital of Guangzhou Medical University | Phase 1 |
| Active Not Recruiting | A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC NCT02905591 | Joseph J. Cullen, MD, FACS | Phase 2 |
| Unknown | The Tracking Molecular Evolution for NSCLC (T-MENC) Study NCT03838588 | Geneplus-Beijing Co. Ltd. | — |
| Unknown | A Mobile Supportive Care App for Patients With Metastatic Lung Cancer NCT03512015 | Bocconi University | N/A |
| Completed | Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanc NCT03450330 | Dizal Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Study of Nivolumab for Advanced Cancers in India NCT03444766 | Bristol-Myers Squibb | Phase 4 |
| Unknown | IMRT and Timing in Combination With EGFRTKI for Stage IV Non-small-cell Lung Cancer NCT03258671 | LuBing | N/A |
| Terminated | Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in NSCLC NCT03256721 | Fuzhou General Hospital | Phase 2 |
| Completed | Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lu NCT03088540 | Regeneron Pharmaceuticals | Phase 3 |
| Unknown | A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC NCT02981108 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Terminated | Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small NCT02963610 | Fox Chase Cancer Center | Phase 1 / Phase 2 |
| Unknown | EGFR-TKI Resistance Profile in Chinese Patients With Advanced EGFRm+ NSCLC NCT02988141 | Jianxing He | — |
| Completed | Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC NCT03044626 | AIO-Studien-gGmbH | Phase 2 |
| Completed | Atezolizumab as Induction Therapy in Non-small Cell Lung Cancer NCT02994576 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 2 |
| Unknown | EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism NCT03002844 | Shanghai Pulmonary Hospital, Shanghai, China | Phase 2 |
| Terminated | A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer NCT02967133 | Alliance Foundation Trials, LLC. | Phase 2 |
| Completed | Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment NCT02973789 | NovoCure GmbH | Phase 3 |
| Unknown | Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGF NCT02972333 | Shandong Cancer Hospital and Institute | Phase 3 |
| Unknown | Effects of Acupuncture Stimulation on Systemic Inflammation NCT02951611 | RenJi Hospital | N/A |
| Unknown | Apatinib Mesylate Combined With Pemetrexed in the Treatment of Pretreated Advanced Non-squamous Non-small Cell NCT02974933 | Wuling Ou | Phase 2 |
| Unknown | cSMART Liquid Biopsy and Dynamic Monitor of NSCLC Patients in Inner-Mongolia China NCT02980536 | Berry Genomics Co., Ltd. | — |
| Terminated | Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations NCT02954523 | Chul Kim | Phase 1 / Phase 2 |
| Terminated | MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors NCT02669914 | Washington University School of Medicine | Phase 2 |
| Withdrawn | Mature Dendritic Cell Vaccination Against Unique Immunogenic Peptides in Patients With Non Small Cell Lung Can NCT02419170 | Washington University School of Medicine | EARLY_Phase 1 |
| Completed | Skeletal Muscle Atrophy and Dysfunction in Human Cancer NCT02949076 | University of Vermont | N/A |
| Unknown | Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer NCT03050411 | Peking University Third Hospital | Phase 1 |
| Withdrawn | Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC) NCT02705339 | Washington University School of Medicine | Phase 2 |
| Withdrawn | Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors NCT02537561 | Washington University School of Medicine | Phase 1 |
| Completed | SBRT (Stereotactic Body Radiation Therapy) vs. Surgery in High Risk Patients With Early Stage Lung Cancer NCT02562027 | Washington University School of Medicine | N/A |
| Terminated | Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After E NCT02342353 | Washington University School of Medicine | Phase 1 |
| Completed | Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer NCT02299141 | Washington University School of Medicine | Phase 2 |
| Terminated | Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression NCT02431169 | Washington University School of Medicine | — |
| Terminated | Pazopanib in Molecularly Selected Patients With Advanced NSCLC NCT02193152 | Washington University School of Medicine | Phase 2 |
| Completed | Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy NCT02972216 | Yung Shin Pharm. Ind. Co., Ltd. | — |
| Completed | Comparison of qPCR to IHC and FISH for Detection of ALK Fusion Mutations in FFPE Tissue From NSCLC Patients NCT02010047 | British Columbia Cancer Agency | N/A |
| Completed | Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous No NCT01999673 | Peregrine Pharmaceuticals | Phase 3 |
| Unknown | Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC) NCT01312337 | Samsung Medical Center | Phase 2 |
| Unknown | Chemotherapy With or Without Radiosurgery for Asymptomatic Oligo Brain Metastasis NCT01301560 | Samsung Medical Center | Phase 3 |